The DiNAQOR’s research team realised from the start of their project that any mutation could potentially impact the outcome of the work they were doing. As a result, they implemented a thorough quality control process. Stem Genomics’ iCS-digital™ PSC 24-probe kit is part of it and used to routinely check the genomic stability of their hiPSCs.
DiNAQOR is pioneering targeted advanced genetic therapies for cardiomyopathies and heart failure, two leading causes of death with significant unmet medical need. The platform the team has developed uses human induced pluripotent stem cells (hiPSCs) to create a test bed for gene therapy. They produce cardiomyocytes and Engineered Heart Tissues (EHT) from their cell lines.
The DiNAQOR’s research team realised from the start of the project that any mutation could potentially impact the outcome of the work they were doing. As a result, they implemented a thorough quality control process to check the genomic stability of their hiPSCs at the acquisition of a new cell line, before the Master and Working cell banks, and after gene editing (CRISPR-Cas9).
DiNAQOR had acquired a digital PCR machine at the laboratory when they came across the Stem Genomics’ kit solution. Kurt Jacobs, Research Scientist says, “The iCS-digital TM PSC 24-probe kit covers a wide range of mutations in a simple test. It helps us strengthen our quality control at various stages of our workflow. For instance, it picked up the 20q amplicon that was present in some of our hiPSC lines.”
Kurt adds, “The test is really precise and fast. It helps us standardize and enhance the quality of our final differentiated cells. Additionally, we find it really easy to use: I had never done a digital PCR test before I used it and it was successful the first time I tried it! We also find that in case you need it, the team at Stem Genomics is very responsive to support your needs and queries.”
DiNAQOR is a genetic medicine platform company focused on advancing novel solutions for patients suffering from severe, inherited forms of heart disease.
Please enter your e-mail address.